The present invention is related to compositions containing extracellular vesicles (exosomes) and methods of using the same for increasing lifespan of fetus, viability of fetus, or viability of newborn, for treating inflammation in uterus and/or fetus, for delaying preterm birth, or for treating a condition related to inflammation in uterus and/or fetus, wherein the extracellular vesicles comprising a nuclear factor kappa beta (NF-κB) inhibitor and a photo-specific binding protein.

Pharmaceutical compositions comprising spray-dried oxalate decarboxylase crystals are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using compositions comprising spray-dried oxalate decarboxylase crystals are also disclosed.

Pharmaceutical compositions comprising spray-dried oxalate decarboxylase crystals are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using compositions comprising spray-dried oxalate decarboxylase crystals are also disclosed.

The present invention provides engineered methionine gamma lyase polypeptides and compositions thereof. The engineered methionine gamma lyase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) conditions. The present invention also relates to the use of the compositions comprising the engineered methionine gamma lyase polypeptides for therapeutic purposes.

The present invention provides engineered methionine gamma lyase polypeptides and compositions thereof. The engineered methionine gamma lyase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) conditions. The present invention also relates to the use of the compositions comprising the engineered methionine gamma lyase polypeptides for therapeutic purposes.

Disclosed are methods and compositions which can be used to treat diseases or disorders associated with an elevated amount of oxalate, including, for example, hyperoxaluria, in particular enteric hyperoxaluria.

Disclosed are methods and compositions which can be used to treat diseases or disorders associated with an elevated amount of oxalate, including, for example, hyperoxaluria, in particular enteric hyperoxaluria.

The technology described herein is directed to compositions and methods for modulating serotonin in a subject. Described herein are compositions comprising viable or non-viable serotonin modulating bacteria, conditioned medium(s) of serotonin-modulating bacteria, cell pellet(s) of serotonin modulating bacteria, and/or metabolites and/or proteins derived from serotonin-modulating bacteria. Also described herein are methods of treating serotonin-related disease or disorders.

The technology described herein is directed to compositions and methods for modulating serotonin in a subject. Described herein are compositions comprising viable or non-viable serotonin modulating bacteria, conditioned medium(s) of serotonin-modulating bacteria, cell pellet(s) of serotonin modulating bacteria, and/or metabolites and/or proteins derived from serotonin-modulating bacteria. Also described herein are methods of treating serotonin-related disease or disorders.

Phenylalanine ammonia-lyase (PAL) variants with a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL for therapeutic uses, including the treatment of adolescent subjects having PKU.